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Background: Nitisinone is used to treat hereditary tyrosinemia type 1 (HT-1)
by preventing accumulation of toxic metabolites, including succinylacetone
(SA). Accurate quantification of SA during newborn screening is essential, as is
quantification of both SA and nitisinone for disease monitoring and optimiza-
tion of treatment. Analysis of dried blood spots (DBS) rather than plasma sam-
ples is a convenient method, but interlaboratory differences and comparability
of DBS to serum/plasma may be issues to consider.
Methods: Eight laboratories with experience in newborn screening and/or
monitoring of patients with HT-1 across Europe participated in this study to
assess variability and improve SA and nitisinone concentration measurements
from DBS by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Quantification of nitisinone from both DBS and plasma was performed to
assess sample comparability. In addition, efforts to harmonize laboratory
Abbreviations: DBS, dried blood spot; FAH, fumarylacetoacetate hydrolase; HT-1, hereditary tyrosinemia type 1; LLOQ, lower limit of quantification;
NTBC, 2-(2-nitro-4-trifluoromethyl-benzyl)-1,3-cyclohexanedione, nitisinone; SA, succinylacetone, LC-MS/MS, liquid chromatography-tandem mass
spectrometry.
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procedures of SA and nitisinone quantifications during 5 rounds of analysis are
described.
Results: Nitisinone levels measured from DBS and plasma strongly correlated
(R2 = 0.93). Due to partitioning of nitisinone to the plasma, levels were higher
in plasma by a factor of 2.34. In the initial assessment of laboratory perfor-
mance, all had linear calibrations of SA and nitisinone although there was
large inter-laboratory variability in actual concentration measurements. Subse-
quent analytical rounds demonstrated markedly improved spread and preci-
sion over previous rounds, an outcome confirmed in a final re-test round.
Conclusion: The study provides guidance for the determination of nitisinone
and SA from DBS and the interpretation of results in the clinic. Inter-
laboratory analytical harmonization was demonstrated through calibration
improvements.
KEYWORD S
dried blood spot, hereditary tyrosinemia type 1, nitisinone, succinylacetone, tandem mass
spectrometry
1 | INTRODUCTION
Hereditary tyrosinemia type 1 (HT-1; OMIM reference
276700) is a rare autosomal recessive disorder with an inci-
dence of one in 100 000 worldwide.1 The disease is caused
by a defect in the final enzyme of the tyrosine breakdown
pathway: fumarylacetoacetate hydrolase (FAH; EC
3.7.1.2). The lack of FAH activity results in accumulation
of toxic metabolites such as succinylacetone (SA) and suc-
cinylacetoacetate causing liver damage including hepato-
cellular carcinoma as well as renal dysfunction, neurologic
crisis, and shorter life expectancy than for healthy
individuals.2-4
The care for patients with HT-1 improved dramatically
with the introduction of treatment with nitisinone
(2-(2-nitro-4-trifluoromethyl-benzyl)-1,3-cyclohexanedione
[NTBC]) in the early 2000s (approved by the Food and
Drug Administration in 2002 and the European Medicines
Agency in 2005, Orfadin®). To date, nitisinone is still the
standard of care in combination with strict dietary restric-
tions to minimize phenylalanine and tyrosine intake.
Treatment should be started as early as possible in life and
continue without interruption to improve prognosis.5
Newborn screening programs allow for early HT-1
identification and disease intervention in many countries.6
Urine or blood SA, or its surrogate porphobilinogen
synthase activity, is currently the best screening disease
marker, while tyrosine is less reliable since its levels may
not be consistently raised in individuals with HT-17 and
individuals with other conditions or premature infants
may have elevated tyrosine levels as well.8,9 Accuracy in
SA quantification is essential to avoid false positives but
more importantly to assure there are no false-negative
results during newborn screening. For individuals already
undergoing treatment, monitoring of detectable levels of
SA is important to determine adequacy of treatment.
Normal levels of SA are below 20 nmol/L in plasma,10
well below the lower limit of quantitation (LLOQ) for
most laboratories, where any quantifiable levels of SA
indicate insufficient treatment. It is therefore essential
for laboratories to establish appropriate methods with
low limits of quantification for optimal management of
patient treatment.
While it is essential to keep SA levels as low as possi-
ble, the dose of nitisinone should not be unnecessarily
high since clinical data on long-term usage are sparse
and effects of nitisinone during pregnancy are not fully
known.11 Nitisinone has a presumed half-life of 54 hours
and is typically dosed once or twice daily at 1 mg/kg/
day.12-14 Monitoring nitisinone levels in combination
with SA thus serve as a tool facilitating disease manage-
ment, dose optimization, detection of inter-individual
variability, and monitoring treatment compliance. Easy
monitoring would increase the possibilities to provide the
best care possible and help individuals that, for example,
find treatment compliance challenging.15 Monitoring
using dried blood spots (DBS) has advantages to address
this problem since samples can be taken by the patient/
caregiver at home, are less invasive, are relatively stable,
can be easily transported to the laboratory via normal
postal services, and many laboratories already offer home
monitoring of tyrosine on DBS to confirm dietary
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adherence where a single assay could thereby provide
reductions in laboratory costs.16-19
Here, we describe a study to evaluate the current ana-
lytical performance of SA and nitisinone measurements
from DBS between different laboratories involved in
patient monitoring across Europe. Moreover, we describe
efforts taken to harmonize laboratory measurement pro-
cedures and highlight important aspects to consider
when assessing nitisinone and SA levels in the clinic.
Harmonized results allow comparable information to be
generated regardless of methodology or site of analysis,
thus improving patient information and outcomes.20
2 | METHODS
2.1 | Study design
The initial phase of the study aimed at evaluating the
current analytical performance of seven different labora-
tories on the determination of SA and nitisinone from
DBS by assessing any variability in concentrations
reported. The comparability of nitisinone levels measured
from plasma samples to samples prepared as DBS was
further investigated.
The second phase aimed at harmonizing results and
improving the intra- and inter-laboratory differences of
eight (a new laboratory group which did not participate
in the initial phase joined the project for SA determina-
tion only) different laboratories through analysis of the
respective standards in relation to results precision.
A total of five assay rounds were performed. DBS
materials enriched with predetermined SA and nitisinone
concentrations were prepared and sent blinded to the
participating laboratories for analysis. New test samples
were distributed for each round. The laboratories submit-
ted results of the blinded samples to the central scientist
who collated the results and a review and analysis meet-
ing was held after each round to evaluate assay improve-
ment and advice for further improvements in the
subsequent round.
2.2 | Laboratories
Eight laboratories with experience in either newborn
screening or monitoring of patients with HT-1 or both
across Europe were included in the study for harmoniza-
tion of measurements: ULB, Laboratoire de Pédiatrie,
Brussels, Belgium; WellChild Laboratory at Evelina
London Children's Hospital, London, UK; Screening-
Labor Hannover, Hannover, Germany; Laboratory
of Metabolic Diseases, University Medical Center
Groningen, Groningen, The Netherlands; Clinical Chem-
istry and Pharmacology Lab, Meyer Children's University
Hospital, Florence, Italy; Laboratorio de Metabolopatias,
Hospital Clínico Universitario de Santiago, Santiago de
Compostela, Spain; Department of General Pediatrics,
Neonatology, and Pediatric Cardiology, University Hospi-
tal Düsseldorf, Germany; and Newborn Screening &
Biochemical Genetics, Birmingham Children's Hospital,
Birmingham, UK.
2.3 | Sample preparations
Nitisinone (Sobi, Sweden) was dissolved in dimethyl sulf-
oxide (DMSO) to generate a 12 mM stock solution which
was diluted ×100 in whole blood from which sample
standards were generated. SA (4-6-dioxoheptanoic acid;
Sigma-Aldrich, D1415) was dissolved in PBS to generate
a 2 mM stock and finally diluted ×100 in whole blood
which was already enriched with nitisinone. Standard
solutions in Round 4 contained 4.42, 17.7, 44.5, 88.8 μM
nitisinone and 0.0, 0.36, 2.19, 4.37, 10.9 μM SA, and stan-
dard solutions in Round 5 contained 3.84, 7.69, 23.1, 57.6,
115 μM SA. To prepare the DBS, 25 μL blood sample was
pipetted on the DMPK-C cards (FTA DMPK-C cards, Cat
no WB129243, GE Healthcare) and dried at room temper-
ature overnight. DBS samples were sent blinded to all
participating laboratories by regular mail at room tem-
perature. For analysis Round 1, 2 sets of samples differing
only with regard to the anticoagulant (Li-Heparin or
ethylenediaminetetraacetic acid [EDTA]) were tested.
For analysis Rounds 2 and 3, a series of unknown con-
centrations of SA and nitisinone were distributed. For
Rounds 4 and 5, an additional set of standard samples
were distributed to be used for uniform calibration in all
laboratories.
2.4 | Liquid chromatography-tandem
mass spectrometry
All analyses in all participating laboratories were performed
using liquid chromatography-tandem mass spectrometry
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96 LAEREMANS ET AL.
(LC-MS/MS). There were considerable differences in
methods for both nitisinone and SA across laboratories.
Only two of the seven laboratories reporting results for both
analytes used the same extract for both assays. The other
five used a separate blood spot punch, and a different
extraction technique for each. All seven laboratories who
reported results for nitisinone used reverse-phase chroma-
tography, with four using a stable isotope labeled internal
standard, two using mesotrione and one using external
standardization. Four of eight laboratories reporting SA
results used reverse-phase chromatography while the other
four used flow injection; all used stable isotope labeled SA
as internal standard, and five formed a derivative as part of
their sample preparation. Details of the technical differences
and methods between laboratories are given in Tables 1
and 2.
2.5 | Statistics
Linear regression analysis was performed to investigate
the correlation between nitisinone calculated from DBS
vs plasma and samples prepared with EDTA vs Lithium-
Heparin. A two-sided t-test was used to evaluate the
impact of the anticoagulant on the results. Expected vs
measured SA and nitisinone concentrations were plotted
and trendlines calculated.
3 | RESULTS
3.1 | Quantification of nitisinone from
DBS and plasma
Nitisinone measurement in plasma by LC-MS/MS is
well established.21 To test if nitisinone levels measured
from plasma samples were comparable to samples pre-
pared as DBS, concentrations in 27 blood samples were
analysed by LC-MS/MS at two different laboratories in
the study (Figure 1). The concentrations significantly
correlated between samples (R2 = 0.9256) indicating
that either way of sample preparation could be used
during clinical assessment of patient samples. The
reported conversion factors between DBS values vs
plasma values vary. A conversion factor of 2.4 in 9 paired
plasma and DBS samples was found by one research
group,21 while a second group derived a factor of 2.6
from 39 paired samples from 13 patients22 (poster
abstract). Our own data indicate a conversion factor
of 2.34.
3.2 | Initial assessment of SA and
nitisinone quantifications
Seven clinical laboratories were included in an initial
evaluation to test if measured SA and nitisinone concen-
trations vary between laboratories to a clinically signifi-
cant extent, which could motivate harmonization of
laboratory measurement procedures. In the first assess-
ment round, all laboratories received 2 × 8 blinded DBS
samples containing both SA and nitisinone, prepared
either from tubes with EDTA or Li-Heparin as anticoag-
ulant. SA and nitisinone were quantified by LC-MS/MS
according to the standard procedure in each laboratory.
Six laboratories returned results for the SA determina-
tion, and all laboratories for nitisinone. There was a
highly linear relationship between the measured and
the expected concentration of both SA and nitisinone
(R2 > 0.9798 for each laboratory). However, most labo-
ratories either over- or underestimated the concentra-
tions to an extent (−23% to +65% for nitisinone, and
− 45% to +570% for SA) which could have a clinical
impact with relation to dosing of nitisinone, particularly
for SA (Figure 2A,B). The use of either Li-Heparin or
EDTA as anticoagulant did not impact the results
(Figure 2C,D).
Several of the laboratories had incorrect assessment
of the lower concentrations of SA or of samples absent
of added SA (Figure S1A,B), motivating technical
improvements in preparations for the following analysis
FIGURE 1 Quantification of nitisinone from dried blood
spots (DBS) and plasma. Samples from patients treated with
nitisinone analysed from plasma and from DBS. Each dot
represents data from one patient (N = 27). DBS values multiplied
by conversion factor of 2.34
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round. Most problems were due to extraction difficulties
and calibration differences. Thus, taken together the
first assessment round showed a need for improving lab-
oratory performance for quantification of both
nitisinone and SA.
3.3 | Improving analytical quality of SA
and nitisinone quantification
The agreement between laboratories in assessing SA
and nitisinone improved in the following analysis
FIGURE 2 A, Assessment of succinylacetone (SA) concentration from dried blood spots (DBS). Blood samples spiked with 0.0, 0.3,
1.0, 5.0, 25.0, 100.0 μM SA were assessed by six laboratories. Trend lines were drawn to illustrate linear relationship (all R2 values >0.99).
Dotted lines represent results from tubes using ethylenediaminetetraacetic acid (EDTA) as anticoagulant and solid lines represent results
from tubes using Li-Heparin. Outliers not shown in figure: Laboratory 2 had values of 571.0 (EDTA) and 538.0 (Li-Heparin) for the
100.0 μM sample. B, Difference plot comparing succinylacetone (SA) results from DBS prepared from blood tubes using EDTA as
anticoagulant and those from tubes using Li-Heparin showing no significant difference (P > .05). C, Assessment of nitisinone
concentration from DBS. Blood samples spiked with 0.0, 5.0, 10.0, 25.0, 50.0, 150.0 μM nitisinone were assessed by seven laboratories.
Trend lines were drawn to illustrate linear relationship (all R2 values >0.97). Dotted lines represent results from tubes using EDTA as
anticoagulant and solid lines represent results from tubes using Li-Heparin. D, Difference plot comparing nitisinone results from DBS
prepared from blood tubes using EDTA as anticoagulant and those from tubes using Li-Heparin showing no significant
difference (P > .05)
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round: the quality in Round 2 was considered good
but there were still discrepancies attributable to cali-
bration (between laboratory slope bias against added
amount). This persisted in Round 3. It was
also considered by the study group that some of the
added levels both of SA and nitisinone were too high
and not reflecting concentrations found clinically
(Figure S1A,B).
For analysis Round 4, samples with lower concentra-
tions of both SA and nitisinone were distributed to test
FIGURE 3 Outcomes of analysis Rounds 4 and 5. A, Measured succinylacetone (SA) and nitisinone concentrations plotted against the
expected concentrations demonstrate markedly improved spread and precision. B, Bias plots of percentage deviation from target values of
measured SA and nitisinone concentrations demonstrate improved accuracy and precision in Round 5
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assay performance in a concentration range that was clini-
cally more relevant than that tested in previous rounds. In
addition, new liquid standards were included to test if cali-
bration with the same samples would improve assay perfor-
mance. In this round, the spread and precision markedly
improved over the previous rounds (Figure 3A,B).
In Round 5, the standardization was retested with the
same type of samples and preparations of Round 4 and
the improvement seen in Round 4 was confirmed
(Figure 3A,B).
A summary of which laboratory participated in which
analysis round is presented in Table S1.
4 | DISCUSSION
From the observed results of this study, one of our over-
arching goals is to provide guidance and highlight pitfalls
for other clinical laboratories and researchers about the
quantification of SA and nitisinone specifically on DBS.
DBS is an attractive alternative to plasma to use for the
clinical follow-up of patients. It offers the patients the
opportunity to perform the sampling themselves without
loss of quality and clinical value of the results for the
physician and the patients.
However, quantification of different substances in
DBS is challenging and many physicians doubt the accu-
racy of the results from a DBS. This doubt can be the con-
sequence of interlaboratory differences of reported values
and lack of knowledge about the matrix and methods. It
is therefore important to overcome the differences
between laboratories. These differences are the conse-
quence of poor recovery of the substances, poor limits of
quantification, calibration issues or calculation errors.
Therefore, we strive to harmonize the existing protocols
for SA and nitisinone to that level that results between
laboratories are comparable.
All contributing laboratories shared their protocols,
instruments, and chemicals used, in order to start the eval-
uation. In the first step, all laboratories used their daily
used methods without any modifications. However, it
should be stated that some of the laboratories were just
starting with these methods and were not offering a day-to-
day clinical service. This first round of data, together with
the comparison of the methods, led to a first modification
of local protocols as well as a harmonization across proto-
cols. Furthermore, we excluded some of the potential inter-
ferences like the differences in the type and use of blood
tubes. The results clearly indicated no significant influence
of the anticoagulant of the blood tubes.
A second step in order to come to a harmonized proto-
col was to use the same calibration standards. An indepen-
dent industrial partner provided external quality control
samples but also standard curves. Use of common calibra-
tion material further reduced the slight differences between
the laboratories, indicating the importance of correct selec-
tion of standard curves with the means available.
In the process of method comparisons, laboratories
referred to the calibrator supplied with the device and
thus achieved a significantly better agreement in the
given concentrations, however, specific modifications to
the methods contributed to the improvement in reported
analytical values. These modifications were related to the
extraction temperature where individual laboratories
modified their method from 40C to 60C for SA and
40C to room temperature for nitisinone. LC temperature
was modified by individual laboratories from room tem-
perature to 40C while the extraction time for SA was
changed from 45 to 30 minutes. In addition, a change in
LC-column for nitisinone was made by a laboratory from
Luna C18 to Gemini NX-C18.
As described above, correct understanding of the
meaning of the reported values of these two markers by
physicians is crucial. Even after initiating nitisinone treat-
ment, SA concentrations in urine decrease rapidly and are
usually not detectable after 1 to 2 days. But in blood SA
concentrations decrease more slowly. The half-life of SA is
approximately 12 days (unpublished calculations from the
data of the initial registration study for nitisinone “the
NTBC study”). It takes well over a month before SA in
blood becomes unquantifiable and therefore within nor-
mal limits. For nitisinone on the other hand, the half-life
is approximately 2 days (1 day in newborns).23,24 A steady-
state concentration is obtained after 12 days dosing.24
A limitation of the study is that time/stability and
temperature stability studies were not performed, and
data on time of analysis at each laboratory from prepara-
tion of samples were not collected for the calculation of
recovery rates. However, only about one-third of the
increased concentrations of SA is measured from DBS.
The recovery rate for SA of about 30% is thereby much
lower than for nitisinone which is about 95%.
A DBS external quality control scheme including
nitisinone and SA is now available from an independent
provider. However, further work is still needed in the
future to harmonize the quantification of nitisinone and
SA with LC-MS/MS, preferably by performing a study
enabling data providing scientific evidence for develop-
ment of a standard protocol.
In conclusion, this article provides guidance for the
determination of nitisinone and SA from DBS and the inter-
pretation of results in the clinic. Furthermore, inter-
laboratory analytical improvements were demonstrated
through calibration improvements. This should be mini-
mized through the use of common reference samples across
laboratories. DBS show to be a good matrix for regular
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clinical follow-up of patients with a minimum of burden for
the patients and optimal clinical surveillance and guidance.
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